Breakthrough in Vaccine Research: Potential for Universal Protection
Imagine if one vaccine could shield us from various bacteria, common allergens, and respiratory viruses. A recent study involving mice presents a promising experimental vaccine that could pave the way for that kind of universal defense.
However, it’s worth noting that this research is still in the animal testing stage. Before it gets the green light for human use, it will need to undergo numerous trials to ensure it’s safe and effective.
Published on February 19 in the journal Science, this study introduces a nasal-spray vaccine that operates differently from traditional vaccines.
Typically, vaccines train the immune system to recognize specific antigens, like proteins on the surface of a virus. The immune system then gears up to remember and attack that antigen if encountered again. Sure, this creates a solid immune defense, but it can be quite narrow. If the targeted antigen mutates, well, that defense might falter.
Some researchers are actively looking into vaccines that focus on “highly conserved” antigens—those that don’t change much over time. Such vaccines might target numerous strains of viruses at once, like various influenza or coronavirus strains. But the team behind this new nasal-spray vaccine took a somewhat different path. Instead of just activating the adaptive immune system, which is responsible for remembering specific antigens, they also stimulated the innate immune system—our body’s generic first line of defense.
“What’s fascinating about the innate system is its ability to protect against a wide array of different microbes,” said Bali Pulendran, a professor of microbiology and immunology at Stanford University School of Medicine.
This concept of activating both the innate and adaptive immune systems isn’t completely new. The Bacillus Calmette-Guérin (BCG) tuberculosis vaccine is known to trigger this dual protection. This was even explored early in the pandemic to see if BCG might offer broader protection against COVID-19.
Pulendran and his team previously examined the BCG vaccine in mice, discovering that it caused lung immune cells to send out specific signals that kept the innate immune cells engaged for months instead of fading quickly.
The novel nasal-spray vaccine, named GLA-3M-052-LS+OVA, mimics those signals. It also includes a safe egg-protein antigen that recruits the appropriate immune cells to the lungs. Their findings show that mice given three doses over three weeks demonstrated protection against SARS-CoV-2, other coronaviruses, the bacteria Staphylococcus aureus and Acinetobacter baumannii, and even allergens from house dust mites for at least three months afterward.
In tests, the vaccinated mice managed to fend off these threats thanks to the activated innate immune response and were able to mount an adaptive immune response quickly. On the flip side, unvaccinated mice suffered significantly more—higher inflammation, noticeable weight loss, and a greater risk of death from viruses and bacteria, along with serious allergic reactions to the allergens.
“This is really exciting research,” noted Daniela Ferreira, a professor at the University of Oxford. She wasn’t part of the study but indicated that if the results hold up in human trials, it could revolutionize how we manage common respiratory infections.
Pulendran also stressed that for now, the focus remains on lab animals. There’s still a mountain of work to be done before it can transition to human testing. He believes that if proven safe and effective, this vaccine could really change the game—making vaccinations simpler and better preparing us for emerging respiratory threats. He thinks that perhaps just two doses could offer protection for people.
